XML 64 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)
 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Cash flows from operating activities:    
Net loss $ (31,612,000) $ (16,137,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 525,000 1,169,000
Amortization of deferred financing costs and debt discount 961,000 605,000
Joint venture acquisition obligation accretion 362,000 204,000
Provision for doubtful accounts 1,126,000 938,000
Provision for expired enzyme 313,000 0
Change in fair value of warrant liability (134,000) (418,000)
Change in fair value of option liability 0 (2,250,000)
Share-based compensation expense 2,566,000 2,723,000
Equity loss from investment in joint venture 0 48,000
Loss on asset disposal 15,000 257,000
Gain on previously held equity interest in joint venture 0 (4,892,000)
Gain on sale of assets 0 (4,392,000)
Loss on debt extinguishment 0 708,000
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Accounts receivable 2,505,000 361,000
Inventories (1,158,000) (975,000)
Other current assets (19,000) 69,000
Other assets (124,000) (117,000)
Accounts payable and accrued expenses (666,000) (1,080,000)
Deferred revenues, related party 0 (638,000)
Deferred revenues 47,000 (1,245,000)
Long-term deferred rent (81,000) (2,000)
Net cash used in operating activities (25,374,000) (25,064,000)
Cash flows from investing activities:    
Purchases of property and equipment (792,000) (536,000)
Expenditures for intellectual property (255,000) 0
Proceeds from Puregraft divestiture 0 5,000,000
License agreement termination fee (400,000) (600,000)
Cash acquired in purchase of the joint venture 0 5,000
Net cash (used in) provided by investing activities (1,447,000) 3,869,000
Cash flows from financing activities:    
Principal payments on long-term obligations (1,303,000) (22,292,000)
Proceeds from long-term obligations 0 27,000,000
Debt issuance costs and loan fees 0 (1,744,000)
Joint venture purchase payments (2,236,000) (141,000)
Proceeds from exercise of employee stock options and warrants 4,066,000 147,000
Proceeds from sale of common stock 19,075,000 3,001,000
Costs from sale of common stock (425,000) (184,000)
Net cash provided by financing activities 19,177,000 5,787,000
Effect of exchange rate changes on cash and cash equivalents (13,000) (104,000)
Net decrease in cash and cash equivalents (7,657,000) (15,512,000)
Cash and cash equivalents at beginning of period 15,506,000 25,717,000
Cash and cash equivalents at end of period 7,849,000 10,205,000
Cash paid during period for:    
Interest 1,972,000 1,592,000
Supplemental schedule of non-cash investing and financing activities:    
Fair value of warrants allocated to (from) additional paid-in capital (296,000) 949,000
Fair value of intangible assets acquired 0 9,394,000
Fair value of tangible assets acquired 0 260,000
Joint venture purchase obligation 0 4,709,000
Fair value of previously held equity interest at acquisition date $ 0 $ 4,928,000